| Home | E-Submission | Sitemap | Editorial Office |  
top_img
    
SPECIAL ARTICLE 2019 March 18
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016
Purpose This study presents the 2016 nationwide cancer statistics in Korea, including cancer incidence, survival, prevalence, and mortality. Materials and Methods Cancer incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database and follo...
SPECIAL ARTICLE 2019 March 18
Prediction of Cancer Incidence and Mortality in Korea, 2019
Purpose This study aimed to report on cancer incidence and mortality for the year 2019 to estimate Korea’s current cancer burden. Materials and Methods Cancer incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database, and cancer mortali...
ORIGINAL ARTICLE 2018 June 1
Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
Purpose Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic challenge. [V4 Q5 ]dDAVP is a vasopressin peptide analog with previously reported anticancer activity against carcinoma tumors. By acting as a selective agonist of arginine vasopressi...
ORIGINAL ARTICLE 2018 June 6
Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells
Purpose Pim kinases are highly conserved serine/threonine kinases, and different expression patterns of each isoform (Pim-1, Pim-2, and Pim-3) have been observed in various types of human cancers, including gastric cancer. AZD1208 is a potent and selective inhibitor that affect...
Current Issue
Volume 51(2); Apr 2019
Volume 51(1); January 2019
Volume 50(4); October 2018
RSS feed

Accepted and E-pub version articles are published online before they appear in a regular issue of the journal. Accepted articles are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. The accepted article remains on this page until the final proof version of the paper is posted in Epub Ahead-of Print page.
Accepted article is given its own Doi, so it can be citable as it has been linked to PubMed.

It may be cited as shown in the following example:
Park IH, Im SA, Jung KH, Sohn JH, Park YH, Lee KS, et al. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). Cancer Res Treat. 2018 Feb 14 [Epub]. https://doi.org/10.4143/crt.2017.562.

Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Cancer Research and Treatment 2017; 49(4): 915-926.
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community